PMID- 26630992
OWN - NLM
STAT- MEDLINE
DCOM- 20160930
LR  - 20191210
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 233
IP  - 5
DP  - 2016 Mar
TI  - Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to 
      dexamphetamine on an auditory oddball task using electroencephalography: a 
      single-dose study.
PG  - 863-71
LID - 10.1007/s00213-015-4165-x [doi]
AB  - RATIONALE: Piperazine-based designer drugs such as benzylpiperazine (BZP) and 
      trifluoromethylphenylpiperazine (TFMPP) have been marketed and sold as legal 
      alternatives to dexamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) until 
      2008 in New Zealand. When administered in combination, BZP + TFMPP have been 
      reported to produce drug-drug synergism in rodents by stimulating the release of 
      dopamine and serotonin. OBJECTIVES: This study was to evaluate the acute 
      event-related potential effects of BZP, TFMPP or the combination of BZP + TFMPP 
      compared with dexamphetamine in young healthy male adults. METHODS: A 
      double-blind, randomised, placebo-controlled study investigated the effects of 
      BZP, TFMPP, the combination of BZP + TFMPP, and dexamphetamine on the 
      event-related potentials during an auditory oddball task. Healthy, right-handed 
      males were given a single oral dose of either BZP (200 mg), TFMPP (60 mg), a 
      combination of BZP + TFMPP (100/30 mg), dexamphetamine (20 mg) or placebo 
      (lactose) and tested both before and 120 min after drug administration. RESULTS: 
      A single dose of either TMFPP (t = -2.29, p = 0.03) or dexamphetamine (t = -2.33, 
      p = 0.02) significantly reduced the P300 amplitude. A similar trend was also 
      found in BZP. In contrast, BZP and TFMPP in combination has no effect. Neither 
      P300 latency nor the mean reaction time was affected by any of the drug 
      treatments. In addition, neither the P100 nor the P200 component was 
      significantly affected following any of the drug treatments. CONCLUSIONS: A 
      single oral dose of BZP or TFMPP, but not the combination of BZP/TFMPP, affected 
      auditory sensory-evoked P300 potential in a manner similar to dexamphetamine.
FAU - Lee, HeeSeung
AU  - Lee H
AD  - School of Pharmacy, Faculty of Medical and Health Sciences, The University of 
      Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
AD  - Centre for Brain Research, Faculty of Medical and Health Sciences, The University 
      of Auckland, Auckland, New Zealand.
FAU - Wang, Grace Y
AU  - Wang GY
AD  - Department of Psychology, Auckland University of Technology, Auckland, New 
      Zealand.
FAU - Curley, Louise E
AU  - Curley LE
AD  - School of Pharmacy, Faculty of Medical and Health Sciences, The University of 
      Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
AD  - Centre for Brain Research, Faculty of Medical and Health Sciences, The University 
      of Auckland, Auckland, New Zealand.
FAU - Sollers, John J
AU  - Sollers JJ
AD  - Department of Psychological Medicine, Faculty of Medical and Health Sciences, The 
      University of Auckland, Auckland, New Zealand.
FAU - Kydd, Rob R
AU  - Kydd RR
AD  - Department of Psychological Medicine, Faculty of Medical and Health Sciences, The 
      University of Auckland, Auckland, New Zealand.
AD  - Cognitive Neuroscience Research Group, School of Psychology, The University of 
      Auckland, Auckland, New Zealand.
FAU - Kirk, Ian J
AU  - Kirk IJ
AD  - Cognitive Neuroscience Research Group, School of Psychology, The University of 
      Auckland, Auckland, New Zealand.
AD  - Centre for Brain Research, Faculty of Medical and Health Sciences, The University 
      of Auckland, Auckland, New Zealand.
FAU - Russell, Bruce R
AU  - Russell BR
AD  - School of Pharmacy, Faculty of Medical and Health Sciences, The University of 
      Auckland, Private Bag 92019, Auckland, 1142, New Zealand. 
      b.russell@auckland.ac.nz.
AD  - Centre for Brain Research, Faculty of Medical and Health Sciences, The University 
      of Auckland, Auckland, New Zealand. b.russell@auckland.ac.nz.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20151203
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Designer Drugs)
RN  - 0 (Piperazines)
RN  - 25R3ONU51C (1-(3-trifluoromethylphenyl)piperazine)
RN  - 333DO1RDJY (Serotonin)
RN  - 3UG152ZU0E (1-benzylpiperazine)
RN  - TZ47U051FI (Dextroamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Central Nervous System Stimulants/*pharmacology
MH  - Designer Drugs/*pharmacology
MH  - Dextroamphetamine/*pharmacology
MH  - Discrimination, Psychological/drug effects
MH  - Dopamine/metabolism
MH  - Double-Blind Method
MH  - Drug Synergism
MH  - Electroencephalography/*drug effects
MH  - Event-Related Potentials, P300/drug effects
MH  - Humans
MH  - Male
MH  - Piperazines/*pharmacology
MH  - Psychomotor Performance/*drug effects
MH  - Reaction Time/drug effects
MH  - Serotonin/metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - BZP
OT  - Combination of BZP and TFMPP
OT  - Human ERP
OT  - P300
OT  - TFMPP
EDAT- 2015/12/04 06:00
MHDA- 2016/10/01 06:00
CRDT- 2015/12/04 06:00
PHST- 2015/09/17 00:00 [received]
PHST- 2015/11/18 00:00 [accepted]
PHST- 2015/12/04 06:00 [entrez]
PHST- 2015/12/04 06:00 [pubmed]
PHST- 2016/10/01 06:00 [medline]
AID - 10.1007/s00213-015-4165-x [pii]
AID - 10.1007/s00213-015-4165-x [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2016 Mar;233(5):863-71. doi: 
      10.1007/s00213-015-4165-x. Epub 2015 Dec 3.